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Background
IL-1 is a major mediator of the inflammatory cascade in
Familial Mediterranean Fever (FMF) and an established
therapeutic target [1].
Objective
To retrospectively assess the efficacy and safety of the
IL-1 inhibitor Canakinumab in adult and adolescent
FMF patients, including cases resistant to the IL-1
receptor antagonist anakinra.
Methods
Twelve patients (7 men) with genetically confirmed FMF,
fulfilling the Tel Hashomer criteria, aged 32.5 years (med-
ian, range 13-70), with median disease duration of 168
months and active disease refractory to colchicine (n=8)
and/or anakinra (n=4), received Canakinumab 150mg sub-
cutaneously every 4 (n=7) or 6 (n=3) or 8 weeks (n=2) for
a median of 12 months (range 4-46). Canakinumab was
given as monotherapy in 9; 3 patients received concomi-
tant treatment with colchicine and/or corticosteroids.
Clinical and laboratory parameters during follow-up were
recorded.
Results
Seven out of 12 patients (58%) achieved complete clinical
remission within a median time of one month. Normaliza-
tion of all laboratory parameters associated with inflam-
mation occurred in 70% of patients within a median time
of 2 months and in all, but one, of these patients complete
clinical remission was also reached. Response was
maintained until the last visit in all patients with clinical
and/or serological complete remission. The remaining
patients achieved partial responses, with persisting, albeit
milder, arthralgias and abdominal pain, and lower, but
abnormal CRP levels. Overall, the concomitant corticos-
teroid dose was significantly reduced during follow up.
The recently proposed FMF50 score for assessing outcome
in FMF (2) was achieved by 67% and 88% of patients at
one month and 12 months, respectively. Canakinumab
was well tolerated; one patient experienced an urinary
tract infection, which resolved with antibiotics.
Conclusion
The rapid and sustained response to Canakinumab in
the majority of our patients, together with the favorable
safety profile, encourages its further use in FMF.
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